Prospective, multi-center post-marketing surveillance cohort study to monitor the safety of the human papillomavirus-16/18 AS04-adjuvanted vaccine in Chinese girls and women aged 9 to 45 years, 2018-2020

• Main Authors: Qianhui Wu (Author), Mengcen Qian (Author), Sarah Welby (Author), Adrienne Guignard (Author), Dominique Rosillon (Author), Kusuma Gopala (Author), Yuan Xu (Author), Keruo Liu (Author), Yunkun He (Author), Ning Jiang (Author), Qin Tan (Author), Jiamin Xie (Author), Taoying Zhu (Author), Qizhang Wang (Author), Yingzi Pan (Author), Ruikun Zeng (Author), Jie Yang (Author), Xiaoqian Zhao (Author), Man Zhou (Author), Adoración Navarro-Torné (Author), Hongjie Yu (Author), Dorota Borys (Author)
• Format: Book
• Published: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

ABSTRACTFollowing the approval of Cervarix for the immunization of girls and women in China against high-risk human papillomavirus types 16 and 18, a non-interventional post-authorization safety study was performed. A multi-center prospective cohort study assessed safety following Cervarix vaccinati...